<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358345</url>
  </required_header>
  <id_info>
    <org_study_id>PHP C9</org_study_id>
    <nct_id>NCT00358345</nct_id>
  </id_info>
  <brief_title>PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization</brief_title>
  <official_title>PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the ability of the PreView PHP(study&#xD;
      device)to detect newly diagnosed non-treated Choroidal Neovascularization (CNV)lesion&#xD;
      associate with advanced Age-related Macular Degeneration (AMD) or Myopia and differentiate&#xD;
      them from Intermediate AMD or Geographic Atrophy (GA)or patients with high Myopia with no&#xD;
      CNV.&#xD;
&#xD;
      This study secondary is to enhance NotalVision normative database.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study is prospective, multi-center, comparative study.&#xD;
&#xD;
        -  A clinical trail with FDA approval device (510K).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">347</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Intermediate AMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Newly diagnosed CNV</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        At least 200 subjects with intermediate AMD in at least one (1) eye based on medical record&#xD;
        review and/or clinical diagnosis and at least 200 subjects with neovascular AMD in at least&#xD;
        one (1) eye.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed (up yo 2 months) CNV OR Intermediate AMD&#xD;
&#xD;
          -  Age &gt;50 for AMD subjects&#xD;
&#xD;
          -  Age &gt;18 for Myopic subjects&#xD;
&#xD;
          -  VA 20/160 or better in the study eye&#xD;
&#xD;
          -  Mental and physical ability to performed a PHP test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of macular disease other than AMD or high myopia in the study eye.&#xD;
&#xD;
          -  Previous surgical or laser treatment within the macular erea.&#xD;
&#xD;
          -  Concurrent intraocular drug therapy (within 30 days).&#xD;
&#xD;
          -  Present of any significant media opacity that preclude a clear veiw of the macula.&#xD;
&#xD;
          -  Any non macular related ocular surgery performed within 3 months prior to the study.&#xD;
&#xD;
          -  CNV subjects inability to tolerate intravenous fluorscien angiography.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofer Sharon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Notal Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel Aviv Sourasky medical center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>July 27, 2006</study_first_submitted>
  <study_first_submitted_qc>July 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2006</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Osnat Ehrman</name_title>
    <organization>NotalVision</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

